Andrew Sampson, MD
Interventional Cardiology · Raleigh, NCNPI 1891911384
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,000 of the $47,616 with a category attached, or 60.9%. Edwards Lifesciences accounts for 83.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $21,349 and has fallen 90.0% since, to $2,143 in 2025.
Across 207 payments — averaging $230.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$40K
- Abbott$3K
- Medtronic$1K
- Boston Scientific$763
- Cvrx, Inc.$623
- Heartflow, Inc.$372
- plus $2K from 20 others
Across 17 payments — averaging $2778.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$33K
- Cardiovascular Systems Inc.$14K
What the payments were for
- Consulting fees$29,00061%
- Grants$660%
- Travel & lodging$8,16817%
- Food & beverage$10,38222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 88 | $39,595 |
| Abbott | 34 | $3,165 |
| Medtronic(2 entities) | 26 | $1,431 |
| Boston Scientific | 10 | $763 |
| Cvrx, Inc. | 4 | $623 |
| Heartflow, Inc. | 7 | $372 |
| Shockwave Medical, Inc | 3 | $296 |
| Abiomed | 2 | $279 |
| Inari Medical, Inc. | 2 | $181 |
| Pfizer | 9 | $154 |
| Siemens Medical Solutions USA, Inc. | 2 | $145 |
| Biotronik Inc. | 1 | $127 |
| Philips North America LLC | 2 | $114 |
| Irhythm Technologies, Inc. | 2 | $71 |
| Cardiovascular Systems Inc. | 1 | $50 |
| Atricure, Inc. | 2 | $50 |
| Angiodynamics, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Amgen | 1 | $24 |
| Teleflex LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Terumo Medical Corporation | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| AstraZeneca | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$28,414
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,882
- PASCAL$1,210
- AMPLATZER Occluders$546
- Barostim Neo System$524
- CoreValve Evolut$519
- SAPIEN 3 Ultra RESILIA$332
- Xience Sierra Coronary Stent System$296
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$280
- FFRct$254
- Mitra Clip system$221
- NAVITOR$205
- Diamondback Coronary$194
- AMPLATZER$180
- FLOWTRIEVER CATHETER, S$168
- CT THROMBECTOMY SYSTEM KIT$168
- OPTICROSS$166
- XIENCE V$162
- AVVIGO Guidance System$160
- COREVALVE EVOLUT R$156
How this compares
$47,616 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $119,285 |
| EntrestoSacubitril/Valsartan | 27 | $47,988 |
| Repatha SureclickEvolocumab | 46 | $34,199 |
| Metoprolol Succinate | 127 | $1,979 |
| Nebivolol Hcl | 32 | $1,647 |
| Atorvastatin Calcium | 103 | $925 |
| Valsartan | 33 | $832 |
| ClopidogrelClopidogrel Bisulfate | 71 | $814 |
| Rosuvastatin Calcium | 61 | $523 |
| Losartan Potassium | 41 | $475 |
| Amlodipine Besylate | 53 | $393 |
| Carvedilol | 33 | $309 |
| Spironolactone | 66 | $291 |
| Nitroglycerin | 14 | $221 |
| Warfarin Sodium | 18 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $154 | $119,28595 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$1.6M
- Robert JobeRaleigh$191K
- James ZidarRaleigh$57K
- Willis WuRaleigh$56K
- Islam OthmanRaleigh$50K
- Dwijesh PatelRaleigh$40K
- Siva KethaRaleigh$19K
- Mohit PasiRaleigh$16K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.